Patents by Inventor Andrew George Popplewell

Andrew George Popplewell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody Molecules Which Bind to Human IL-17
    Publication number: 20100086538
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Application
    Filed: June 25, 2007
    Publication date: April 8, 2010
    Applicant: UCB PHARMA S.A.
    Inventors: Stephen Edward Rapecki, Andrew George Popplewell, Ralph Adams
  • BIOLOGICAL PRODUCTS
    Publication number: 20100021995
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: September 23, 2008
    Publication date: January 28, 2010
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman
  • Framework Selection
    Publication number: 20090326203
    Abstract: The present invention relates to improved methods for the selection of appropriate human acceptor framework regions for non-human (donor) antibodies and methods for obtaining humanized antibodies of high affinity using such acceptor frameworks.
    Type: Application
    Filed: June 26, 2007
    Publication date: December 31, 2009
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Alastair David Griffiths Lawson, Andrew George Popplewell, Kerry Louise Tyson
  • Biological Products
    Publication number: 20090269840
    Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
    Type: Application
    Filed: October 30, 2007
    Publication date: October 29, 2009
    Applicant: CELLTECH R&D LIMITED
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Karen Zinkewich-Peotti, Robert Kendall Morrison
  • Antibody molecules having specificity for human IL-1?
    Patent number: 7608694
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-1?, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: October 27, 2009
    Assignee: UCB Pharma S.A.
    Inventors: Alastair David Griffiths Lawson, Andrew George Popplewell
  • Neutralising Antibody Molecules Having Specificity for Human IL-17
    Publication number: 20090117126
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: November 16, 2005
    Publication date: May 7, 2009
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Biological products
    Patent number: 7452976
    Abstract: There are disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: November 18, 2008
    Assignee: UCB Pharma S.A.
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Karen Zinkewich-Peotti, Robert Kendall Morrison
  • BIOLOGICAL PRODUCTS
    Publication number: 20080269465
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Application
    Filed: June 18, 2008
    Publication date: October 30, 2008
    Applicant: UCB PHARMA S.A.
    Inventors: DILJEET SINGH ATHWAL, DEREK THOMAS BROWN, ANDREW NEIL CHARLES WEIR, ANDREW GEORGE POPPLEWELL, ANDREW PAUL CHAPMAN, DAVID JOHN KING
  • Expression control using variable intergenic sequences
    Patent number: 7419659
    Abstract: The present invention relates to a method of production of antibodies wherein the heavy and light chains of a particular antibody molecule are encoded by the DNA present in a dicistronic message in which the two cistrons are linked by an optimised intergenic sequence.
    Type: Grant
    Filed: December 5, 2002
    Date of Patent: September 2, 2008
    Assignee: UCB Pharma S.A.
    Inventor: Andrew George Popplewell
  • Antibody molecules specific to human tumor necrosis factor alpha
    Patent number: 7402662
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: July 22, 2008
    Assignee: UCB Pharma S.A.
    Inventors: Dilijeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Biological products
    Patent number: 7355011
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: April 8, 2008
    Assignee: UCB Pharma S.A.
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman
  • Production of humanised antibodies to TNF?
    Patent number: 7186820
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: March 6, 2007
    Assignee: UCB Celltech
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Biological products
    Patent number: 7012135
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF?. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF?.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: March 14, 2006
    Assignee: Celltech Chiroscience Limited
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Calicheamicin derivative-carrier conjugates
    Publication number: 20040192900
    Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.
    Type: Application
    Filed: November 3, 2003
    Publication date: September 30, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Paul David Robbins, Andrew George Popplewell
  • Calicheamicin derivative-carrier conjugates
    Publication number: 20040082764
    Abstract: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.
    Type: Application
    Filed: May 2, 2003
    Publication date: April 29, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Arthur Kunz, Justin Keith Moran, Joseph Thomas Rubino, Neera Jain, Eugene Joseph Vidunas, John McLean Simpson, Paul David Robbins, Nishith Merchant, John Francis DiJoseph, Mark Edward Ruppen, Nitin Krishnaji Damle, Andrew George Popplewell
  • Biological products
    Publication number: 20030235869
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: May 2, 2003
    Publication date: December 25, 2003
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman
  • Biological products
    Publication number: 20030026805
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF&agr;. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF&agr;.
    Type: Application
    Filed: October 18, 2001
    Publication date: February 6, 2003
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King
  • Biological products
    Publication number: 20020151682
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNF&agr;. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNF&agr;.
    Type: Application
    Filed: September 10, 2001
    Publication date: October 17, 2002
    Inventors: Diljeet Singh Athwal, Derek Thomas Brown, Andrew Neil Charles Weir, Andrew George Popplewell, Andrew Paul Chapman, David John King